Table 5.

Analysis for 3-line gain from baseline at 1 Year

Baseline Characteristics	N	≥3-line gain (%)	Adjusted OR (95% CI) §	P-value
Age (years)
50–69	131	51(38.9%)	1.00	0.008
70–79	387	107(27.6%)	0.62 (0.37, 1.02)
80–89	512	141(27.5%)	0.44 (0.27, 0.73)
≥90	75	28(37.3%)	0.67 (0.32, 1.41)
Baseline VA in study eye
68–82 letters, 20/25 - 20/40	397	28(7.1%)	0.11 (0.07, 0.18)	<0.0001
53–67 letters, 20/50 - 20/80	414	150(36.2%)	1.00
38–52 letters, 20/100–20/160	223	119(53.4%)	2.60 (1.80, 3.77)
23–37 letters, 20/200-20/320	71	30(42.3%)	1.73 (0.97, 2.07)
Baseline VA in fellow eye
83–100 letters, 20/20 or better	331	110(33.2%)	1.00	0.005
68–82 letters, 20/25 - 20/40	433	135(31.2%)	0.90 (0.63, 1.30)
0–67 letters, 20/50 or worse	341	82(24.0%)	0.53 (0.35, 0.80)
Baseline area of CNV (mm2)
≤2.54	443	145(32.7%)	1.00	0.04
>2.54 to ≤5.08	219	63(28.8%)	0.71 (0.47, 1.07)
>5.08 to ≤10.2	207	65(31.4%)	0.91 (0.60, 1.37)
>10.2	103	24(23.3%)	0.67 (0.38, 1.18)
Can’t measure	133	30 (22.6%)	0.44 (0.25, 0.76)
RAP lesion
No	966	276(28.6%)	1.00	0.006
Yes	118	48(40.7%)	1.94 (1.21, 3.10)
Total foveal thickness (μ)
1st quartile (≤325)	277	59(21.3%)	1.00	0.004
2nd quartile (>325 to ≤425)	285	95(33.3%)	1.74 (1.11, 2.72)
3rd quartile (>425 to ≤550)	253	83(32.8%)	1.15 (0.73, 1.82)
4th quartile (>550)	285	89(31.2%)	0.80 (0.50, 1.27)
RPE elevation
No	145	61(42.1%)	1.00	0.002
Yes	944	258(27.3%)	0.52 (0.34, 0.79)
Treatment Group
Ranibizumab Monthly	284	97 (34.2%)	1.00	0.04
Bevacizumab Monthly	265	83 (31.3%)	0.80 (0.53, 1.22)
Ranibizumab as needed	285	71 (24.9%)	0.56 (0.37, 0.86)
Bevacizumab as needed	271	76 (28.0%)	0.63 (0.41, 0.96)

OR = Odds Ratio; CI = Confidence Interval; VA= Visual Acuity; CNV= choroidal neovascularization; RAP=Retinal Angiomatous Proliferans; RPE=Retinal Pigment Epithelium.

^§A total of 1066 participants were included in the final multivariate model, and 39 patients were excluded due to missing value in one or more predictors.